Secoisolariciresinol

Secoisolariciresinol is a plant lignan found primarily in flaxseeds that converts to enterolignans in the gut microbiome. It reduces cholesterol through HMG-CoA reductase inhibition and may lower breast cancer risk by modulating estrogen metabolism.

Origin & History

Secoisolariciresinol diglucoside (SDG) is a plant lignan primarily found in flaxseed (Linum usitatissimum), where it exists as the main lignan component bound to glucose molecules. It is extracted from defatted flaxseed meal using methods like alkaline hydrolysis or microwave-assisted germination, followed by purification to concentrate the lignans.

Historical & Cultural Context

While SDG-specific traditional use lacks strong evidence, flaxseed has been consumed for millennia in Western and Ayurvedic traditions for digestive health and inflammation. Modern focus on isolated SDG stems from 1990s flaxseed research rather than historical lignan isolation.

Health Benefits

• May reduce LDL cholesterol in men: A 2024 RCT showed significant reduction in LDL-C and total cholesterol in men taking 60mg/day for 12 weeks (moderate evidence)
• Potential breast cancer risk reduction: A Phase IIB RCT found SDG reduced Ki-67 proliferation marker by 2.2% in premenopausal high-risk women (preliminary evidence)
• Anti-inflammatory effects: Preclinical studies show SDG activates Nrf2/HO-1 pathway while inhibiting NF-κB (animal evidence only)
• Cardiovascular support: Animal studies suggest ACE inhibition properties, though human confirmation lacking (preliminary evidence)
• Antioxidant activity: Metabolites enterodiol and enterolactone demonstrate antioxidant effects through multiple pathways (mechanistic evidence)

How It Works

Secoisolariciresinol diglucoside (SDG) is converted by gut bacteria into enterolignans enterodiol and enterolactone, which act as selective estrogen receptor modulators (SERMs). These metabolites inhibit HMG-CoA reductase, reducing cholesterol synthesis, and compete with endogenous estrogens at estrogen receptors. The compound also modulates aromatase activity and enhances sex hormone-binding globulin production.

Scientific Research

Two key human RCTs have evaluated SDG: a 2024 trial (PMC11111469) with 74 participants showing LDL cholesterol reduction in men at 60mg/day, and a 2020 Phase IIB trial (PMID: 32312713) with 180 premenopausal women showing modest Ki-67 reduction at 50mg/day. No meta-analyses were identified, and other studies remain preclinical.

Clinical Summary

A 2024 randomized controlled trial demonstrated that 60mg daily secoisolariciresinol significantly reduced LDL cholesterol and total cholesterol in men over 12 weeks, representing moderate-quality evidence. A Phase IIB randomized trial found SDG reduced Ki-67 proliferation markers by 2.2% in premenopausal women at high breast cancer risk. However, evidence remains limited with small sample sizes and short-term follow-up periods. More large-scale, long-term studies are needed to confirm therapeutic efficacy.

Nutritional Profile

Secoisolariciresinol (SDG) is a pure lignan compound, not a whole food, so traditional macronutrient/micronutrient profiling does not apply. As an isolated phytochemical compound: Molecular weight: 362.46 g/mol. Chemical class: Plant lignan (dibenzylbutanediol). Not a source of calories, protein, fat, fiber, vitamins, or minerals in supplemental form. Bioactive compound concentration in common dietary sources: flaxseed is the richest known source at 75–800 mg SDG per 100g dry weight (varies by variety and processing); sesame seeds contain ~29–37 mg/100g; sunflower seeds ~0.6 mg/100g; rye bread ~0.07–0.09 mg/100g. In supplement form, standardized flaxseed lignans typically deliver 50–600 mg SDG per dose. Bioavailability notes: SDG is not absorbed intact; gut microbiota convert SDG to enterolignans enterodiol (ED) and enterolactone (EL), which are the primary circulating bioactive forms. Conversion efficiency varies significantly based on gut microbiome composition, antibiotic use, and diet. Peak plasma enterolignans reached approximately 8–10 hours post-ingestion. Fat co-ingestion may modestly improve absorption. Enterolactone plasma concentrations after 60 mg/day SDG supplementation in RCT conditions reached approximately 20–40 nmol/L. SDG also exhibits weak phytoestrogenic activity via its enterolignan metabolites, with affinity for estrogen receptor beta (ERβ) >> ERα.

Preparation & Dosage

Clinically studied doses range from 50-60mg/day of pure SDG compound. Cardiovascular effects: 60mg/day (as 2x30mg capsules) for 12 weeks. Breast cancer risk reduction: 50mg/day standardized extract for 12 months. Flaxseed sources provide 10-30mg SDG per 30g serving. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Omega-3 fatty acids, vitamin E, probiotics, green tea extract, resveratrol

Safety & Interactions

Secoisolariciresinol is generally well-tolerated with minimal reported adverse effects in clinical trials. Due to its estrogenic activity, it may interact with hormone replacement therapy and tamoxifen, potentially altering their effectiveness. Women with hormone-sensitive conditions like breast or endometrial cancer should consult healthcare providers before use. Safety during pregnancy and lactation has not been established, so avoidance is recommended.